Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharvaris NVPHVS -1.15%22 3-Year EBITDA Growth Rate is -7.10% as of Jun. 2026. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,127 Biotechnology companies, Pharvaris NV ranks worse than 76.93% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -7.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -21.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Pharvaris NV was -7.10% per year. The lowest was -135.40% per year. And the median was -38.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Pharvaris NV 3-Year EBITDA Growth Rate Related Terms
PHVS vs PGEN, NKTR, VERA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Pharvaris NV's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharvaris NV 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharvaris NV's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Pharvaris NV's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -7.10% mean?
Pharvaris NV (PHVS) has a 3-Year EBITDA Growth Rate of -7.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pharvaris NV and its competitors. According to the industry distribution chart, Pharvaris NV ranks #867 out of 1127 companies in the Biotechnology industry, placing it in the top 76.9%.
Is Pharvaris NV's 3-Year EBITDA Growth Rate too high?
Pharvaris NV's current 3-Year EBITDA Growth Rate is -7.10%. Based on the distribution chart, Pharvaris NV ranks #867 out of 1127 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's 3-Year EBITDA Growth Rate compare to PGEN and NKTR?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #867 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Pharvaris NV in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pharvaris NV and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharvaris NV's current 3-Year EBITDA Growth Rate is -7.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current 3-Year EBITDA Growth Rate of -7.10%. The current 3-Year EBITDA Growth Rate is -7.10%. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current 3-Year EBITDA Growth Rate is -7.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score
Get the complete analysis for PHVS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHVS has been successfully added to your 
